AbbVie and Iambic enter AI-driven drug discovery collaboration across immunology, neuroscience and oncology

AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

The partnership will combine AbbVie's therapeutic expertise with Iambic's Enchant v3 and broader molecular-superintelligence platform to identify and optimise new small-molecule drug candidates.

Iambic will receive an upfront payment and is eligible for development and commercial milestones plus tiered royalties, although detailed financial terms were not disclosed.

Field	Content
Alert Type	Deal
Companies	AbbVie; Iambic Therapeutics
Deal Type	Multi-year drug discovery collaboration
Asset or Company	Enchant v3 and Iambic molecular-superintelligence platform
Therapy Area(s)	Immunology; neuroscience; oncology
Technology or Modality	Artificial intelligence; computational drug discovery; small molecules
Deal Value	Upfront payment plus development and commercial milestones and tiered royalties; financial amounts not disclosed
Geography	Global
What Happened	AbbVie and Iambic entered a multi-year collaboration to apply Iambic's AI-driven discovery platform to selected targets across immunology, neuroscience and oncology.
Why It Matters	The agreement adds another major pharmaceutical partner to Iambic's platform and reflects growing use of AI to accelerate small-molecule discovery and optimisation.
Supporting Context	Iambic's Enchant platform is designed to integrate molecular structure, chemistry and biological data to predict properties and guide drug design.
Strategic Rationale	AbbVie gains access to specialised AI discovery capabilities while Iambic receives funding and potential downstream economics tied to successful programmes.
Potential Impact	The collaboration could shorten discovery cycles and expand the number of tractable targets across several high-value therapeutic areas.
Key Takeaway	AbbVie is partnering with Iambic to apply AI-driven drug discovery across immunology, neuroscience and oncology.
What to Watch	Selection of programme targets, candidate nominations and progression of AI-designed molecules into preclinical development.
Primary Source	AbbVie
Relevant Date	21 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com